Authors
Loading...
Analysis demonstrates significant improvement in myelofibrosis grades in patients with CMPN, suggesting Ruxolitinib enhances survival rates.
Viveros et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: